Morgan Stanley analyst Maxwell Skor raised the firm’s price target on Insmed (INSM) to $108 from $102 and keeps an Overweight rating on the shares as part of a Q2 earnings preview. The firm continues to view the potential brensocatib launch favorably. It cites increasing confidence into the potential bronchiectasis launch for the target bump.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on INSM: